Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Porter

Showing results (81-90 of 199) with videos related to

Pageof 20
Sort By:
Journal for Immunotherapy of Cancer|December 28, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphomaSattva S Neelapu, Sherry Adkins, Stephen M Ansell, et al.
Transplantation and Cellular Therapy|June 30, 2022
Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with MyelofibrosisCraig W Freyer, Daria V Babushok, Noelle V Frey, et al.
Journal of Hematotherapy & Stem Cell Research|June 14, 2003
Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantationJohn Gerecitano, Clarissa Mathias, Rosemarie Mick, et al.
American Journal of Hematology|March 26, 2016
Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomasClinton Yam, Daniel J Landsburg, Kevin T Nead, et al.
Transplantation and Cellular Therapy|January 23, 2025
Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell TherapyLuke Maillie, Sunita D Nasta, Jakub Svoboda, et al.
Clinical Lymphoma|July 3, 2003
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibodyDonald E Tsai, Ivan Maillard, Stephen J Schuster, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 9, 2017
Erythropoietic protoporphyria in an adult with sequential liver and hematopoietic stem cell transplantation: A case reportAnnika L Windon, Rashmi Tondon, Nathan Singh, et al.
Transplantation and Cellular Therapy|October 1, 2021
Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signatureRodney Macedo, Chloé Pasin, Alex Ganetsky, et al.
The New England Journal of Medicine|March 27, 2013
Chimeric antigen receptor-modified T cells for acute lymphoid leukemiaStephan A Grupp, Michael Kalos, David Barrett, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 21, 2023
One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplantLindsey Chippendale, Craig W Freyer, Alison Carulli, et al.
Pageof 20

Showing results (81-90 of 199) with videos related to

Sort By:
Pageof 20
Journal for Immunotherapy of Cancer|December 28, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphomaSattva S Neelapu, Sherry Adkins, Stephen M Ansell, et al.
Transplantation and Cellular Therapy|June 30, 2022
Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with MyelofibrosisCraig W Freyer, Daria V Babushok, Noelle V Frey, et al.
Journal of Hematotherapy & Stem Cell Research|June 14, 2003
Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantationJohn Gerecitano, Clarissa Mathias, Rosemarie Mick, et al.
American Journal of Hematology|March 26, 2016
Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomasClinton Yam, Daniel J Landsburg, Kevin T Nead, et al.
Transplantation and Cellular Therapy|January 23, 2025
Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell TherapyLuke Maillie, Sunita D Nasta, Jakub Svoboda, et al.
Clinical Lymphoma|July 3, 2003
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibodyDonald E Tsai, Ivan Maillard, Stephen J Schuster, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 9, 2017
Erythropoietic protoporphyria in an adult with sequential liver and hematopoietic stem cell transplantation: A case reportAnnika L Windon, Rashmi Tondon, Nathan Singh, et al.
Transplantation and Cellular Therapy|October 1, 2021
Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signatureRodney Macedo, Chloé Pasin, Alex Ganetsky, et al.
The New England Journal of Medicine|March 27, 2013
Chimeric antigen receptor-modified T cells for acute lymphoid leukemiaStephan A Grupp, Michael Kalos, David Barrett, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 21, 2023
One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplantLindsey Chippendale, Craig W Freyer, Alison Carulli, et al.
Pageof 20